CORD-19:4ca5d854d3f99440b507fd7dfae73c8ad6fc45d5 / 788786-789139 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"T75636","span":{"begin":0,"end":353},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The NRC is dedicated to constrain the increase of resistances by recommending susceptibility testing in patients after the first treatment failure and in patients who have undergone antibiotic therapies at multiple occasions due to unrelated bacterial infections, as noted down in the S3-guideline \"Helicobacter pylori and gastroduodenal ulcer disease\"."}

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T202","span":{"begin":0,"end":353},"obj":"Sentence"}],"text":"The NRC is dedicated to constrain the increase of resistances by recommending susceptibility testing in patients after the first treatment failure and in patients who have undergone antibiotic therapies at multiple occasions due to unrelated bacterial infections, as noted down in the S3-guideline \"Helicobacter pylori and gastroduodenal ulcer disease\"."}

    CORD-19-PD-MONDO

    {"project":"CORD-19-PD-MONDO","denotations":[{"id":"T2259","span":{"begin":242,"end":262},"obj":"Disease"},{"id":"T2260","span":{"begin":338,"end":351},"obj":"Disease"},{"id":"T5416","span":{"begin":242,"end":262},"obj":"Disease"},{"id":"T14225","span":{"begin":338,"end":351},"obj":"Disease"}],"attributes":[{"id":"A2259","pred":"mondo_id","subj":"T2259","obj":"http://purl.obolibrary.org/obo/MONDO_0005113"},{"id":"A2260","pred":"mondo_id","subj":"T2260","obj":"http://purl.obolibrary.org/obo/MONDO_0043839"},{"id":"A59667","pred":"mondo_id","subj":"T5416","obj":"http://purl.obolibrary.org/obo/MONDO_0005113"},{"id":"A31877","pred":"mondo_id","subj":"T14225","obj":"http://purl.obolibrary.org/obo/MONDO_0043839"}],"text":"The NRC is dedicated to constrain the increase of resistances by recommending susceptibility testing in patients after the first treatment failure and in patients who have undergone antibiotic therapies at multiple occasions due to unrelated bacterial infections, as noted down in the S3-guideline \"Helicobacter pylori and gastroduodenal ulcer disease\"."}